Scholarlink

<p>Denosumab is approved for the treatment of osteoporosis and selected bone tumors, with its efficacy well documented in the literature. However, its use in children for benign bone tumors remains off-label. We report the case of a&#xa0;13-year-old boy with an aneurysmal bone cyst of the humerus who developed severe hypercalcemia following the cessation of supportive denosumab therapy. The patient was successfully treated with intravenous fluid therapy, potassium supplementation, zoledronate, and furosemide. This case highlights the necessity for close monitoring of calcium and bone metabolism in children and adolescents during and after denosumab treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rebound-Hyperkalzämie nach Denosumab-Therapie bei einem 13-jährigen Jungen mit aneurysmatischer Knochenzyste des Humerus – ein Fallbericht

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Beatrice Jung,
  • Frank Traub,
  • Tilmann Busse,
  • Eren Demir

摘要

Denosumab is approved for the treatment of osteoporosis and selected bone tumors, with its efficacy well documented in the literature. However, its use in children for benign bone tumors remains off-label. We report the case of a 13-year-old boy with an aneurysmal bone cyst of the humerus who developed severe hypercalcemia following the cessation of supportive denosumab therapy. The patient was successfully treated with intravenous fluid therapy, potassium supplementation, zoledronate, and furosemide. This case highlights the necessity for close monitoring of calcium and bone metabolism in children and adolescents during and after denosumab treatment.